SEASTAR MEDICAL HOLDING CORP (ICU) Stock News

USA - NASDAQ:ICU - US81256L2034 - Common Stock

0.6133 USD

-0.02 (-2.68%)

Last: 10/17/2025, 8:20:01 PM

0.6041 USD

-0.01 (-1.5%)

After Hours: 10/17/2025, 8:20:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ICU Latest News, Press Relases and Analysis

All

Press Releases

21 days ago - By: SeaStar Medical

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

25 days ago - By: Benzinga - Mentions: ABOS CYCN POAI PSTV ...

12 Health Care Stocks Moving In Thursday's Intraday Session

4 months ago - By: Benzinga

What Does the Market Think About SeaStar Medical Holding?

25 days ago - By: Stocktwits

SeaStar Medical Stock Jumps On Safety Board Backing For Kidney Trial; Retail Eyes Another Run Despite After-Hours Plunge

25 days ago - By: SeaStar Medical

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

a month ago - By: SeaStar Medical

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

2 months ago - By: SeaStar Medical

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

2 months ago - By: SeaStar Medical

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

2 months ago - By: SeaStar Medical

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: SeaStar Medical

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

2 months ago - By: SeaStar Medical

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

3 months ago - By: SeaStar Medical

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

3 months ago - By: SeaStar Medical

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

3 months ago - By: SeaStar Medical

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

3 months ago - By: SeaStar Medical

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

3 months ago - By: SeaStar Medical

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

4 months ago - By: SeaStar Medical

SeaStar Medical Announces Positive Nasdaq Listing Determination